The evaluation of beta-adrenergic blockade in cardiac arrhythmias is difficult because of the complex nature of the arrhythmias and the varied modes of action of blocking drugs. Studies have confirmed the therapeutic value of the betaadrenergic blocking drug pronethalol (Alderlin) (Vaughan Williams, 1963 ; Stock and Dale, 1963 ; Payne and Senfield, 1964; Wolfson et al., 1966) and its more potent successor, propranolol (Inderal) in the management of many different atrial and ventricular arrhythmias (Harrison et al., 1965; Sloman et al., 1965 ; Stock, 1966; Harris, 1966; Szekely et al., 1966; Cherchi et al., 1966; Rochet and Vastesaeger, 1966; Gettes and Surawicz, 1966; Luria et al., 1966; Epstein and Braunwald, 1966) .
This study reports our experience in the management of patients with paroxysmal arrhythmias, acute life-threatening arrhythmias, and recurrent arrhythmias associated with prolonged cardiac arrest. An attempt has also been made to assess the prophylactic value of propranolol in reducing the high incidence of arrhythmias associated with acute myocardial infarction.
Materials and Methods
Thirty-one patients presenting with various cardiac arrhythmias were included in this study. Patients in whom full documentation was not available were not included. There
Presented at a National Heart Foundation of Australia Symposium held in Canberra, 25-27 January 1967. were 19 males and 12 females, with an age range from 17 to 78 (mean 50.9 years). In all these patients the arrhythmia had proved disabling; in some it was associated with prolonged cardiac arrest. Forty-nine patients with acute myocardial infarction were studied to assess the prophylactic value of propranolol in preventing arrhythmias. The When the arrhythmia could be produced by exercise on the treadmill (Cases 1, 3, 7, 8, 11, 14, and 16) after recording the abnormal rhythm the patient was rested, given an intravenous dose of propranolol (0.1 mg./kg. body weight with 1.2 to 2.4 mg. of atropine sulphate), and after 10 minutes the exercise study was repeated (Fig. 1) In the four patients with atrial fibrillation symptoms were controlled in three when propranolol was added to their regimen (Cases 1, 2, and 4). In Cases 1 and 2 the paroxysms continued, but syncope did not occur. In Case 3 syncopal attacks continued to occur with exercise despite full treatment with digitalis, quinidine, and pronethalol. Endocardial pacemaking was then begun; however, the rhythm still alternated between a sinus mechanism and atrial fibrillation. With digitalis and pacing alone syncope continued to occur, but when propranolol was added syncope did not occur.
In the patients with paroxysmal atrial tachycardia the arrhythmia was suppressed provided the dose of propranolol was maintained, except in Case 5, where digoxin was necessary as well as the propanolol. When one patient (Case 7) discontinued treatment after three years he experienced one severe attack before resuming therapy. Two of the four patients with other atrial arrhythmias were suffering from a cardiomyopathy (Cases 10 and 11). Despite a failed direct current reversion in Case 11, both patients reverted to a sinus mechanism while receiving propranolol in addition to other medication. The patient with persistent unexplained sinus tachycardia (Case 12)
showed a satisfactory reduction in rate, as did the patient with rapid atrial flutter due to thyrotoxicosis. The arrhythmia in this case reverted to sinus rhythm when the thyrotoxicosis was controlled. In the group with ventricular ectopic beats propranolol reduced the ectopic beats and prevented the syncopal attacks.
Group B: Acute Arrhythmias
The seven patients included in this group had serious arrhythmias of acute onset associated with severe cardiac disease (Table II) , and the dose and route of administration of propranolol varied with the type of the arrhythmia and the urgency of the clinical situation. In two patients the arrhythmia was associated with acute myocardial infarction and in three others coronary artery disease was associated with pulmonary embolism, digitalis toxicity, and a past history of paroxysmal atrial tachycardia respectively. Of the remaining two, one developed multifocal ventricular extrasystoles while undergoing surgery for subarachnoid haemorrhage, while the other had rapid atrial fibrillation associated with an alcoholic cardiomyopathy.
There were two patients with acute myocardial infarction. In one atrial flutter occurred (Case 17). After propranolol the ventricular rate slowed initially, and later there was reversion to sinus rhythm. In the other (Case 21) paroxysmal ventricular tachycardia was rapidly suppressed with oral propranolol (Fig. 2 failure was suppressed when intravenous pronethalol was administered to the patient in whom the arrhythmia had not been controlled with full doses of digitalis (Fig. 3) cardiac massage varied from 20 to 120 minutes before theadministration of propranolol. In one patient (Case 24) propranolol alone was used to terminate ventricular tachycardia. In Case 25 ventricular fibrillation recurred after reversion with direct current counter shock on nine occasions (Fig. 4) . Propranolol was administered after further counter shock and the patient then remained in sinus rhythm. In the other six patients (Cases 26 to 31) propranolol was given before direct current counter shock and in all cases satisfactory cardiac function was restored. All survived at least 12 hours, with four long-term survivors. Of the four deaths only one (Case 28) was due to a complication of drug therapy. This case has been previously reported (Sloman et al., 1965) . Complete heart block developed while the patient was still receiving propranolol by slow intravenous infusion. The drug was not stopped, and the patient died in ventricular standstill. (Table IV) . Apart from atrial, nodal, and ventricular ectopic beats, which were common and of similar incidence in both groups, the incidence of serious arrhythmias was slight. In the group receiving propranolol one patient had two episodes of ventricular fibrillation and another two short episodes of ventricular tachycardia. There were three deaths in the treated group, one due to cardiogenic shock, another to brain damage following resuscitation from ventricular fibrillation, and the third due to ventricular fibrillation which occurred after the patient was discharged from the coronary care unit.
The incidence of non-specific side-effects was nil. One patient developed cardiogenic shock and another Wenckebach heart block after the administration of propranolol, but hypotension and cardiac failure were neither severe nor frequent.
In the control group two patients had short episodes of ventricular tachycardia and another prolonged slow ventricular tachycardia, which required treatment with procainamide. One patient developed ventricular fibrillation while in the coronary care unit and died, while another developed ventricular fibrillation in a general ward and was successfully resuscitated. The remaining two deaths in this group occurred in the general ward after discharge from the coronary care unit, and the mode of death is unknown. There was therefore no indication that propranolol reduced the frequency of arrhythmias in patients with acute myocardial infarction, but to reach a valid statistical conclusion much larger numbers would have to be studied.
Discussion
These clinical observations indicate that beta-adrenergic drugs have an important place in the treatment of acute and chronic arrhythmias irrespective of their origin or cause. These results are in agreement with previously published reports.
Propranolol was found to be useful in controlling the rate of ventricular response in patients with paroxysmal atrial fibril-C lation and flutter. The drug was used with digoxin, and syncope and giddiness no longer occurred. Syncope was also prevented by propranolol and digoxin when combined with endocardial pacing, supporting the work of Harris (1966) , who was able to reduce the number of ventricular ectopic beats occurring during cardiac pacing by the use of oral propranolol when large doses of quinidine and procainamide had not been successful.
The efficacy of propranolol in preventing paroxysmal arrhythmias may be reliably assessed by provoking the arrhythmia by exercise on a treadmill and repeating the exercise on a treadmill after the administration of intravenous propranolol.
There appears to be a special place for the use of propranolol in patients with prolonged cardiac arrest associated with resistant, recurrent ventricular fibrillation. Propranolol has been shown to have an anti-fibrillatory effect, and we believe it should be used when standard resuscitation methods and drugs have not produced a satisfactory cardiac rhythm. It was found that a satisfactory anti-arrhythmic effect could be produced with a dose of Dropranolol much smaller than a recognized beta-blocking dose, supporting the work of Stickney et al. (1966) and Howe and Shanks (1966) , who showed that the drug has a biphasic mode of action. Propranolol should therefore be given in small intravenous doses of 1-2 mg., repeated as necessary, and covered by a full dose of atropine sulphate to prevent overactivity of the unmasked parasympathetic nervous system. As propranolol appears to have an anti-arrhythmic effect which is not due to its beta-blocking effect it would therefore seem reasonable in certain circumstances to use propranolol in combination with isoprenaline. We have used this combination with success in six patients. In Cases 27, 28, 29, and 31 both drugs were used during resuscitation, and in Cases 25 and 26 isoprenaline was used after successful resuscitation without producing further ventricular fibrillation.
In Case 28 complete heart block developed after successful resuscitation. A slow intravenous infusion was continued, whereas cessation of the drug, followed by the administration of isoprenaline and perhaps endocardial pacing, may have led to a successful outcome.
Trials of the prophylactic value of propranolol in acute myocardial infarction were given impetus by the work of Snow (1965) , who reported a mortality of 13% in 52 patients treated with propranolol compared with 29% mortality in a comparable control group of 55 patients. However, in our study of a relatively small group of patients monitored after infarction we found no significant difference in the incidence of arrhythmias. Studies by Clausen (1966) , Balcon et al. (1966) , and Barber et al. (1966) and lignocaine may be used by the intravenous route to suppress these arrhythmias, but why one morphological type of ventricular ectopic will respond to one of the above antiarrhythmic drugs and not to another remains to be studied. Currently, lignocaine is the drug of choice because of its high therapeutic effect compared with its relatively slight negative inotropic effect. It is used in incremental doses up to 200 mg.
Summary
Thirty-one patients with cardiac arrhythmias were treated with beta-adrenergic blocking drugs propranolol and pronethalol. Propranolol was found to be particularly useful in the management of rapid arrhythmias when other antiarrhythmic drugs had not been successful. Beta-adrenergic blockade was of value in reducing the ventricular rate in paroxysmal atrial fibrillation, atrial flutter, and rapid atrial and sinus rhythms. Propranolol also possessed a specific antiarrhythmic effect not clearly related to its beta-adrenergic blocking effect, and was found to be useful in the treatment of ventricular extrasystoles, paroxysmal ventricular tachycardia, ventricular arrhythmias associated with digitalis intoxication, and recurrent and resistant ventricular fibrillation.
Forty-nine (26 treated, 23 control) patients with acute myocardial infarction were studied to assess the prophylactic value of propranolol in reducing arrhythmias in acute myocardial infarction. The drug was administered intravenously initially in a dose of 0.1 mg./kg./body weight together with atropine sulphate 1.2 mg. followed by 10 mg. of propranolol orally four-hourly for three weeks. There was no difference in the incidence of arrhythmias between the two groups.
Our thanks are due to the medical staff, Royal Melbourne Hospital, who allowed us to treat patients under their care. The propranolol used in this study was made available by Dr. Charles Proctor (Medical Director, I.C.I., Australia), to whom we are grateful. Mr (Read et al., 1965) , a number of chronic physical illnesses (Batata et al., 1967) , neurological disease (Grant et al., 1965) , and patients receiving anticonvulsants, barbiturates (Klipstein, 1964; Malpas, 1966) (Forshaw, 1965) . Reynolds (1966 Reynolds ( , 1967 has gone so far as to suggest a causal relation between folate deficiency and certain forms of mental illness, especially affective changes and, in long-standing cases, dementia. There seems, however, to have been little systematic investigation of the incidence of folate deficiency in psychiatric populations.
These reports encouraged me to ascertain the incidence of low serum folate levels in a psychiatric population and its relation to a number of variables, including diagnosis, age, nutrition, physical state, drugs, and chronicity of illness. Though this investigation was not specifically designed to answer the question, it was felt that some clues regarding the possible aetiological significance of folate deficiency in mental illness might appear. 
Method and Material
Serum folate estimations were carried out on consecutive admissions to two psychiatric units 20 miles (32 km.) apart, one a general hospital unit and the other a mental hospital. They were all under my personal care and were admitted over a period slightly exceeding a year. Though the hospitals served the same geographical area they dealt with somewhat different psychiatric populations, the mental hospital tending to admit the more disturbed and more chronic patients. The intakes of both units were studied concurrently in order to ensure that the whole group was representative with respect to diagnosis, age, and sex of those psychiatric patients within the catchment area for whom admission to hospital was judged to be needed. Within individual subcategories of patients there was little variation in folate levels between the two hospitals.
Serum folate estimations were carried out by an adaptation of the method of Waters and Mollin (1961) by which folate activity was measured by reading turbidimetrically the growth of Lactobacillus casei A.T.C.C. 7469 after incubation in the sample solution for 48 hours at 370 C.: the results were calculated from a standard graph. These estimations were carried out in two different laboratories, but the procedures in both were identical.
